Healtcare Bladder Cancer Therapeutics Market | Page 3

•Latin America
•Middle East
•Africa
For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/bladder-
cancer-therapeutics-market-239
Increasing incidence rate, especially in developed regions fueling growth of bladder cancer
therapeutics market
As per stats released by the International Agency for Research on Cancer (IARC), 59% of bladder
cancer cases are observed in developed countries, with Belgium reporting the highest number of
bladder cancer cases.
As per stats released by Cancer Research UK—a charity involved in cancer research and
development—here were around 10,100 new cases reported in the U.K. in 2014. Bladder cancer
accounts for around 3% of all new cancer cases reported in the U.K. As per a study by the American
Society of Clinical Oncology (ASCO), incidence rate of the disease has decreased by around 12%
in the U.K. in the recent past.
According a study by Cancer Research Institute, bladder cancer is more prevalent among men than
women. Around 77,000 new cases were diagnosed in the U.S. in 2016, leading to 16,000 deaths.
Continuous advancements in clinical research resulted into increased survival rate of people
suffering from bladder cancer, which is around 77% observed in last few years. As per the stats of
American Cancer Society, bladder cancer accounts for 5% of all new cancer cases in the U.S.
Some are the major reasons behind bladder cancer are unhealthy habits. Smoking is a major cause
along with that continuous exposure of industrial chemicals, drinking water with high level of
arsenic, family history of bladder cancer, and long-term use of urinary catheters are the other causes
of bladder cancer. In Africa and Middle East schistosomiasis and infested water are the leading
cause of bladder cancer.
North America holds major share in the global bladder cancer therapeutics market, followed by
Europe due to advanced treatments, developed economy, and easy access to advanced healthcare
facilities. The market in APAC region will witness high growth rate in the near future, due to
increasing per capita income, developing economy, government initiatives on improving healthcare
infrastructure, growing FDI in healthcare, and rapidly increasing aging population. As per stats
released by the Department of Industrial Policy and Promotion (DIPP), the healthcare sector in
India witness FDI worth US$ 4.09 billion between April 2000 and September 2016. Also, medical
tourism in the region is a flourishing business, due to easy access to high-quality low-cost treatment
option. According to data released by the India Brand Equity Foundation (IBEF)— a Trust
established by the Department of Commerce, Ministry of Commerce and Industry, Government of
India—the medical tourism industry in India rakes in US$ 3 billion each year. This creates a highly
conducive environment for growth of the bladder cancer therapeutics market in the region.
Conversely, increasing use of generic drugs, high cost of treatment, asymptomatic nature of the
disease and fewer pipeline products inhibit growth of the market. As per data released by the
American Cancer Society, only one drug received approval from FDA in last three decade.
Global Key Players:
The major companies playing key role in bladder therapeutics market are Sanofi S.A., F. Hoffmann-
La Roche AG, Novartis, Pfizer, Eli Lilly and Co., GlaxoSmithKline, Bristol-Myers Squibb,
Allergan Inc, AVI Biopharma Inc., and AstraZeneca plc. Some are the major drugs approved by